Frontiers in Oncology | Cancer Immunity and Immunotherapy

Original Research

Published on 07 Nov 2022

Cabozantinib sensitizes microsatellite stable colorectal cancer to immune checkpoint blockade by immune modulation in human immune system mouse models

in Cancer Immunity and Immunotherapy

Julie Lang
Alexis D. Leal
Juan A. Marín-Jiménez
Sarah J. Hartman
Jeremy Shulman
Natalie M. Navarro
Matthew S. Lewis
Anna Capasso
Stacey M. Bagby
Bethlehem W. Yacob

Frontiers in Oncology

doi 10.3389/fonc.2022.877635

5,237 views
11 citations

Original Research

Published on 07 Nov 2022

Hydrophobicity identifies false positives and false negatives in peptide-MHC binding

in Cancer Immunity and Immunotherapy

Arnav Solanki
Marc Riedel
James Cornette
Julia Udell
George Vasmatzis

Frontiers in Oncology

doi 10.3389/fonc.2022.1034810

3,598 views
6 citations

Original Research

Published on 07 Nov 2022

CXCL12, a potential modulator of tumor immune microenvironment (TIME) of bladder cancer: From a comprehensive analysis of TCGA database

in Cancer Immunity and Immunotherapy

Jinyan Wang
Yizhao Xie
Dongmei Qin
Shanliang Zhong
Xichun Hu

Frontiers in Oncology

doi 10.3389/fonc.2022.1031706

2,312 views
5 citations

Original Research

Published on 07 Nov 2022

Exploring the nucleotide molecular mechanism of compound kushen injection for lung adenocarcinoma based on network pharmacology and molecular docking

in Cancer Immunity and Immunotherapy

Zhangpeng Ye
Xin Yao
Zhubei Chen
Qin Jin
Qingsheng You

Frontiers in Oncology

doi 10.3389/fonc.2022.1013052

2,617 views
4 citations

Review

Published on 07 Nov 2022

Relationship between copper and immunity: The potential role of copper in tumor immunity

in Cancer Immunity and Immunotherapy

Fu Cheng
Geng Peng
Yan Lu
Kang Wang
Qinuo Ju
Yongle Ju
Manzhao Ouyang

Frontiers in Oncology

doi 10.3389/fonc.2022.1019153

13,572 views
79 citations

Original Research

Published on 02 Nov 2022

A novel cervix carcinoma biomarker: Pathological-epigenomics, integrated analysis of MethylMix algorithm and pathology for predicting response to cancer immunotherapy

in Cancer Immunity and Immunotherapy

Yu-Chong Yu
Tian-Ming Shi
Sheng-Lan Gu
Yu-Hong Li
Xiao-Ming Yang
Qiong Fan
Yu-Dong Wang

Frontiers in Oncology

doi 10.3389/fonc.2022.1053800

3,604 views
5 citations

Original Research

Published on 02 Nov 2022

Polyclonal antibody-induced downregulation of HER1/EGFR and HER2 surpasses the effect of combinations of specific registered antibodies

in Cancer Immunity and Immunotherapy

Gretchen Bergado-Báez
Narjara Gonzalez Suarez
Lisset Chao García
Dayana Pérez-Martínez
Diana Rosa Hernández-Fernández
Talia Fundora-Barrios
Antonio Rodríguez-Álvarez
Geidy Diana Díaz-Ordaz
Moshit Lindzen
Yosef Yarden

Frontiers in Oncology

doi 10.3389/fonc.2022.951267

3,252 views
2 citations

Original Research

Published on 31 Oct 2022

Immune marker expression of irradiated mesothelioma cell lines

in Cancer Immunity and Immunotherapy

Faith Chang
Synat Keam
Tracy Seymour Hoang
Jenette Creaney
Suki Gill
Anna K. Nowak
Martin Ebert
Alistair M. Cook

Frontiers in Oncology

doi 10.3389/fonc.2022.1020493

2,740 views
4 citations

Original Research

Published on 31 Oct 2022

Serum cytokines predict efficacy and toxicity, but are not useful for disease monitoring in lung cancer treated with PD-(L)1 inhibitors

in Cancer Immunity and Immunotherapy

Hannah Schindler
Fabienne Lusky
Lea Daniello
Mariam Elshiaty
Lena Gaissmaier
Karolina Benesova
Margarida Souto-Carneiro
Arlou Kristina Angeles
Florian Janke
Florian Eichhorn

Frontiers in Oncology

doi 10.3389/fonc.2022.1010660

4,607 views
13 citations

Original Research

Published on 25 Oct 2022

Shikonin induces ferroptosis in multiple myeloma via GOT1-mediated ferritinophagy

in Cancer Immunity and Immunotherapy

Wenxia Li
Hangjie Fu
Liuyuan Fang
Hui Chai
Tianwen Gao
Zhenzhen Chen
Shenxian Qian

Frontiers in Oncology

doi 10.3389/fonc.2022.1025067

5,810 views
35 citations

Original Research

Published on 25 Oct 2022

The gut microbiota modulates responses to anti–PD-1 and chemotherapy combination therapy and related adverse events in patients with advanced solid tumors

in Cancer Immunity and Immunotherapy

Zhaozhen Wu
Sujie Zhang
Lingling Li
Ziwei Huang
Di Huang
Yi Hu

Frontiers in Oncology

doi 10.3389/fonc.2022.887383

8,377 views
20 citations

Review

Published on 25 Oct 2022

Tumor response assessment on imaging following immunotherapy

in Cancer Immunity and Immunotherapy

Antonia M. Berz
Clarisse Dromain
Naïk Vietti-Violi
Sarah Boughdad
Rafael Duran

Frontiers in Oncology

doi 10.3389/fonc.2022.982983

16,160 views
36 citations

Original Research

Published on 25 Oct 2022

Predicting immunotherapy outcomes in patients with MSI tumors using NLR and CT global tumor volume

in Cancer Immunity and Immunotherapy

Younes Belkouchi
Laetitia Nebot-Bral
Littisha Lawrance
Michele Kind
Clémence David
Samy Ammari
Paul-Henry Cournède
Hugues Talbot
Perrine Vuagnat
Cristina Smolenschi

Frontiers in Oncology

doi 10.3389/fonc.2022.982790

4,764 views
9 citations

Original Research

Published on 24 Oct 2022

Early monocyte response following local ablation in hepatocellular carcinoma

in Cancer Immunity and Immunotherapy

Melanie A. Kimm
Sophia Kästle
Matthias M. R. Stechele
Elif Öcal
Lisa Richter
Muzaffer R. Ümütlü
Regina Schinner
Osman Öcal
Lukas Salvermoser
Marianna Alunni-Fabbroni

Frontiers in Oncology

doi 10.3389/fonc.2022.959987

2,630 views
2 citations

Original Research

Published on 24 Oct 2022

Liver injury during durvalumab-based immunotherapy is associated with poorer patient survival: A retrospective analysis

in Cancer Immunity and Immunotherapy

Linnea A. Swanson
Ihab Kassab
Irene Tsung
Bryan J. Schneider
Robert J. Fontana

Frontiers in Oncology

doi 10.3389/fonc.2022.984940

5,430 views
17 citations

Review

Published on 21 Oct 2022

TCR mimic compounds for pHLA targeting with high potency modalities in oncology

in Cancer Immunity and Immunotherapy

Hans-Peter Gerber
Leonard G. Presta

Frontiers in Oncology

doi 10.3389/fonc.2022.1027548

11,086 views
9 citations